Form 4: ProMIS Neurosciences Director and 10% Owner Significantly Increases Stake Through Warrant Exercises and New Acquisitions

Title 19 Promis, a director and 10% owner of ProMIS Neurosciences Inc., has substantially increased its beneficial ownership through the exercise of existing warrants at a reduced price and the acquisition of new warrants.

Summary

• Title 19 Promis, a director and 10% owner of ProMIS Neurosciences Inc. (PMN), exercised 359,400 common share purchase warrants across three tranches (A, B, and C) on July 25, 2025.
• Tranche A and B warrants, originally exercisable at $2.02 per share, were exercised at a negotiated price of $0.83158 per share, acquiring 119,800 shares from each tranche.
• Tranche C warrants, originally exercisable at $2.50 per share, were also exercised at the negotiated price of $0.83158 per share, acquiring an additional 119,800 shares.
• Following these exercises, Title 19 Promis's beneficial ownership of common shares increased to 2,435,029.
• On July 29, 2025, Title 19 Promis further acquired 539,100 new warrants to purchase common shares at a purchase price of $0.1875 per warrant, with an exercise price of $1.25 per share.
• The remaining Tranche A warrants expire on the earlier of 18 months from issue date or within 60 days of public announcement of 6-month PMN310 data.
• The remaining Tranche B warrants expire on the earlier of 30 months from issue date or within 60 days of public announcement of 12-month PMN310 data.
• The remaining Tranche C warrants expire on July 31, 2029.
• The newly acquired warrants are exercisable and expire five years after their issuance date.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A director and 10% owner significantly increasing their stake, even at a negotiated lower price, indicates strong confidence in the company's future. While the reduced exercise price could be seen as a negative for existing shareholders due to potential dilution, the overall signal of insider commitment is generally positive.

Positives

• A significant increase in beneficial ownership by a director and 10% owner signals strong confidence in the company's future prospects.
• The exercise of warrants provides capital to ProMIS Neurosciences Inc., strengthening its financial position.
• The acquisition of additional warrants further demonstrates a long-term commitment from a key insider.

Negatives

• The exercise of warrants at a significantly reduced price (from $2.02/$2.50 to $0.83158) could be dilutive to existing shareholders if new shares are issued below the prevailing market price.
• The negotiation of a lower exercise price for the warrants may suggest a need for the company to secure capital, potentially at terms favorable to the insider.

Risks

• Potential dilution for existing shareholders due to the issuance of new shares from warrant exercises, especially at a reduced exercise price.
• The expiry of Tranche A and B warrants is tied to the public announcement of PMN310 clinical trial data, introducing a dependency on trial outcomes and timelines.

Future Outlook

The future outlook for the company's PMN310 program is implicitly referenced, as the expiration of certain warrants is contingent upon the public announcement of 6-month and 12-month clinical data from cohorts treated with single ascending doses of PMN310.

Industry Context

This filing reflects an insider's increased investment in a biopharmaceutical company, ProMIS Neurosciences, which is developing therapies, including PMN310, likely for neurodegenerative diseases such as Alzheimer's. Such insider activity can be a significant indicator of confidence in the company's drug development pipeline and future market potential within the competitive biopharma sector.

Related Party Transactions

• Title 19 Promis, as a director and 10% owner of ProMIS Neurosciences Inc., engaged in transactions (warrant exercises and acquisitions) with the issuer, which are considered related party dealings.

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares from warrant exercises, but also a strong positive signal of confidence from a significant insider.
• Company: Receives capital from the warrant exercises, which can support ongoing operations and development.

Next Steps

• Public announcement via press release or Current Report on Form 8-K of 6-month data from cohorts treated with single ascending doses of PMN310.
• Public announcement via press release or Current Report on Form 8-K of 12-month data from cohorts treated with single ascending doses of PMN310.

Key Dates

Recommendation

The significant increase in beneficial ownership by a director and 10% owner, Title 19 Promis, through both warrant exercises and new warrant acquisitions, signals a strong vote of confidence in ProMIS Neurosciences Inc.'s future. While the negotiated lower exercise price for existing warrants could imply some dilution, the overall commitment from a key insider, especially one with a substantial stake, is a powerful positive indicator for long-term investors. This insider buying suggests a belief in the company's underlying value and future prospects, making it a compelling signal for a 'buy' recommendation.

Keywords

ProMIS Neurosciences, PMN, Form 4, Insider Trading, Warrants, Equity Acquisition, Director, 10% Owner, Biotechnology, Pharmaceutical, Alzheimer's, PMN310